ROSE12

Rose12 Therapeutics is a biotechnology company focused on the discovery and development of novel small molecule inhibitors for the treatment of cancer. The company's primary research centers on the autophagy pathway, specifically targeting Unc-51 like autophagy activating kinase 1 (ULK1), a critical regulator of cellular recycling that cancer cells utilize to survive stress and resist therapy. Founded by renowned chemical biologists Kevan Shokat and Nathanael Gray, Rose12 utilizes advanced chemical proteomics to identify and optimize highly selective drug candidates. In May 2023, the company was acquired by Exelixis to integrate its ULK1 program into a broader portfolio of oncology treatments. The goal of the program is to provide new therapeutic options for patients with solid tumors, particularly in combination with other targeted agents.